Sanofi halts MOBILIZE Phase 3 riliprubart trial in refractory CIDP after interim futility call
Share
Listen to the news
Sanofi halts MOBILIZE Phase 3 riliprubart trial in refractory CIDP after interim futility call
  • Sanofi halted the MOBILIZE phase 3 trial of riliprubart in refractory CIDP following an interim review that flagged insufficient efficacy.
  • Results have not been presented; the decision was based on interim findings from an independent data monitoring committee.
  • No new safety concerns were identified in the interim analysis.
  • Sanofi will reassess continuation of other riliprubart studies, including the VITALIZE phase 3 trial in IVIg-treated CIDP patients.
  • The stop is not expected to be financially material, leaving 2026 guidance unchanged.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606100100PRIMZONEFULLFEED1001186828) on June 10, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending